Atezolizumab is a PD-L1 inhibitor with FDA approval for the treatment of various cancer types, including NSCLC, urothelial carcinomas (UC), MM, triple-negative breast cancer, and hepatocellular carcinoma (HCC). This evidence concerns the gene CD274 and hepatocellular carcinoma.